Milestone Scientific

Milestone Scientific, Inc. is a biomedical technology research and development company, which patents, designs, and develops diagnostic and therapeutic injection technologies and instruments. It operates through the following segments: Dental, Medical, and Corporate. The Corporate segment refers to executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments, financing activities, and public company compliance costs. Its solutions include CompuFlo Epidural, CathCheck Verification System, and Single Tooth Anesthesia System. The company was founded on August 17, 1989 and is headquartered in Roseland, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Milestone Scientific reports Q1 revenue, eyes international expansion opportunities

Milestone Scientific's Q1 2024 performance showed revenue over $2.2 million with improved gross margins.
The company's focus on customer relationships and reimbursement strategies is a key strength.
Challenges include revenue decrease and the need for endorsements in the medical space.
Opportunities lie in international expansion, market penetration goals, and increased marketing efforts.

Milestone Scientific reports improved Q2 performance amidst revenue challenges

Milestone Scientific showcased financial improvements in Q2 2024 despite a revenue decrease, with a focus on enhancing operational efficiency and achieving positive cash flow.
The company's strategic partnerships, international expansion plans, and commitment to innovation through intellectual property enhancements signal a path for future growth and market competitiveness.
While facing challenges in revenue generation and operational clarity, Milestone Scientific's strong balance sheet and market positioning offer opportunities for sustained growth and profitability.

Milestone Scientific reports revenue growth and strategic partnerships in Q3

Milestone Scientific shows promising revenue growth and operational improvements in Q3 2024, driven by strong Dental division performance and international sales.
Strategic partnerships and a solid financial position enhance market reach and provide a foundation for future growth.
Challenges include reducing net losses, driving market adoption of CompuFlo, and navigating Medicare coverage expansion, while opportunities exist in reimbursement initiatives and market expansion post-approvals.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agreement provides Premier’s 4,100 hospitals and 200,000 provider members with preferred access to CompuFlo® Epidural System and CathCheck™ Agreement provides Premier’s 4,100 hospitals and 200,000 provider members with preferred access to CompuFlo® Epidural System and CathCheck™

Milestone Scientific Inc. Awarded Group Purchasing Agreement with Premier for CompuFlo® Epidural System and CathCheck™

MLSS has been hit hard by COVID-19, but their dental business has shown strong signs of recovery.

Milestone's CompuFlo Will Deliver

ROSELAND, N.J., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized drug delivery instruments that provides painless and precise injections, today announced that it projects sales for the third quarter ending September 30, 2020 increased sequentially more than five-fold versus the second quarter ending June 30, 2020.

Milestone Scientific Inc. Projects Over Five-Fold Sequential Increase in Dental Sales for Q3 2020 Versus Q2 2020

Milestone Scientific, Inc. (MLSS) CEO Leonard Osser on Q2 2020 Results - Earnings Call Transcript

Milestone Scientific, Inc. (MLSS) CEO Leonard Osser on Q1 2020 Results - Earnings Call Transcript

Milestone Scientific Surges Again

High-Risk, High-Reward Investors Should Love Milestone Scientific

Milestone Scientific Inc. (MLSS) Q3 2019 Results - Earnings Call Transcript

The company is using its profitable business for dental practices as a cash cow to develop its medical business.

Milestone Scientific Looks Like Breaking Out

Milestone Scientific, Inc. (MLSS) CEO Leonard Osser on Q2 2019 Results - Earnings Call Transcript

Milestone Scientific Inc. (MLSS) CEO Len Osser on Q1 2019 Results - Earnings Call Transcript

Milestone Scientific Inc. (MLSS) on Q4 2018 Results - Earnings Call Transcript

News for Milestone Scientific Stock (MLSS)